COST-EFFECTIVENESS ANALYSIS OF FILGOTINIB VERSUS TOFACITINIB AS FIRST-LINE TREATMENTS FOR RHEUMATOID ARTHRITIS IN GREECE

被引：0
|
作者：
Nomikos, N. [1 ]
Naoum, P. [1 ]
Athanasakis, K. [1 ]
Kyriopoulos, I [2 ]
机构：
[1] Univ West Attica, Athens, Greece
[2] London Sch Econ & Polit Sci, London, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE134
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Lei Tian
    Xiaomo Xiong
    Qiang Guo
    Yixi Chen
    Luying Wang
    Peng Dong
    Aixia Ma
    PharmacoEconomics, 2020, 38 : 1345 - 1358
  • [32] A Cost-Effectiveness Analysis of Onabotulinumtoxin A as First-Line Treatment for Overactive Bladder
    不详
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2018, 73 (11) : 629 - 630
  • [33] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Jonathan P. Shepherd
    Charelle M. Carter-Brooks
    Christopher Chermanksy
    International Urogynecology Journal, 2018, 29 : 1213 - 1219
  • [34] A cost-effectiveness analysis of first-line controller therapies for persistent asthma
    Shih, Ya-Chen Tina
    Mauskopf, Josephine
    Borker, Rohit
    PHARMACOECONOMICS, 2007, 25 (07) : 577 - 590
  • [35] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Shepherd, Jonathan P.
    Carter-Brooks, Charelle M.
    Chermanksy, Christopher
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2018, 29 (08) : 1213 - 1219
  • [36] A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma
    Ya-Chen Tina Shih
    Josephine Mauskopf
    Rohit Borker
    PharmacoEconomics, 2007, 25 : 577 - 590
  • [37] Cost-effectiveness of tumor necrosis factor alpha (TNF-alpha) inhibitors as first-line agents in rheumatoid arthritis
    Spalding, JR
    Hay, JW
    VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [38] THE COST-EFFECTIVENESS OF CATHETER ABLATION AS FIRST-LINE TREATMENT
    Aronsson, M.
    Walfridsson, H.
    Janzon, M.
    Walfridsson, U.
    Levin, L. A.
    VALUE IN HEALTH, 2013, 16 (07) : A529 - A529
  • [39] Cost-effectiveness of olanzapine as a first-line treatment: A comment
    Basu, Anirban
    VALUE IN HEALTH, 2006, 9 (05) : 357 - 357
  • [40] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB VERSUS INFLIXIMAB FOR THE PATIENTS WITH RHEUMATOID ARTHRITIS IN KAZAKHSTAN
    Bektur, C.
    Kayir, F.
    Nurgozhin, T.
    VALUE IN HEALTH, 2014, 17 (07) : A379 - A379
12345